A Look at Alexion’s 2016 Guidance
Alexion Pharmaceuticals (ALXN) expects total revenue to lie at the lower end of $3.0 billion–$3.1 billion during 2016.
On June 1, 2016, Alexion Pharmaceuticals (ALXN) won orphan drug designation (or ODD) from the European Commission for ALXN 1210.
Alexion is expanding the label for its key drug Soliris. Along with Soliris, Alexion’s has several other key molecules in the advanced development stage.
Alexion Pharmaceuticals (ALXN) is a leading biotechnology company focusing on developing innovative drugs for life-threatening, ultra-rare diseases.
Soliris is Alexion’s leading drug. It was approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in 2007 and 2011.
Following Brexit, global equity markets experienced a crash. Anticipations of weaker European and British economies are likely reasons for the fall.
Alexion’s stock price has moved in a range of $111–$209 over the past 52 weeks. Currently, it’s trading at $113, close to its 52-week low.
On June 23, 2016, Alexion Pharmaceuticals was trading at a forward price-to-earnings multiple of 16.46x. It was trading at a premium compared to its peers.
According to a Bloomberg survey, 50% of analysts recommend a “buy” for Novo Nordisk, and 50% recommend a “hold.”
Tresiba prescriptions in the United States are rising continually. In April 2016, Tresiba’s monthly volume market share increased to 1.4%.
Novo Nordisk (NVO) operates in two major segments: diabetes and obesity care and biopharmaceuticals. Diabetes care has been Novo’s major business area.
Novo’s adjusted net margin is continuously improving. In fiscal 2016 and fiscal 2017, Wall Street analysts expect further net margin expansion to 34% and 34.6%, respectively.
On June 23, 2016, Novo Nordisk (NVO) was trading at a forward EV-to-EBITDA multiple of 14.14x. It was trading at a premium compared to its peers.
On June 22, 2016, Novo Nordisk (NVO) was trading at a forward PE multiple of 19.03x. It was trading at a premium compared to its peers that are primarily focused on diabetes.
Global big pharmaceutical companies that have major exposure to Europe will be impacted significantly by Brexit. The depreciating euro will impact sales.
On June 23, 2016, Becton Dickinson (BDX) was trading at a forward PE (price-to-earnings) multiple of ~19.8x compared with the industry average of ~21x.
Becton Dickinson (BDX) completed its annual strategic review of its portfolio, which was initiated after the acquisition of CareFusion.
Becton Dickinson (BDX) is focused on consistent growth and expansion across geographies and product segments and has undertaken a number of strategic initiatives towards these ends.
According to analysts’ consensus estimate, Becton Dickinson (BDX) has the potential to return ~3.8% over the next 12 months.
Becton Dickinson has returned ~20% over the last one year. It outperformed the S&P 500 Index, which returned around -1.2% during the same period.